SRAM
INSY

Stone Ridge Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Stone Ridge Asset Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14,227
Closed -$137K – 1417
2017
Q4 		$137K Buy
+14,227
New +$93.1K 0.01% 1305

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stone Ridge Asset Management's INSY Position: Q1 2018 in Review

Stone Ridge Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 14,227 shares — an estimated $137K sold.

Stone Ridge Asset Management first reported a position in INSY in Q4 2017 and held it in 1 quarter. The position peaked at $137K in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Stone Ridge Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Stone Ridge Asset Management sold 14,227 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $137K.
  • Stone Ridge Asset Management first reported a position in Insys Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Stone Ridge Asset Management's Insys Therapeutics, Inc. position peaked at $137K in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Stone Ridge Asset Management's 13F filing for Q1 2018, filed 14 May 2018.